Gastrointestinal Cancer News

The combination of cabozantinib and atezolizumab prolonged PFS compared with sorafenib among patients with previously untreated advanced hepatocellular carcinoma, according to topline data released by one of the agent’s manufacturers.

The C-reactive protein and alpha-fetoprotein in immunotherapy score identified patients with favorable hepatocellular carcinoma disease control and survival, according to a study presented at the International Liver Congress.

A blood-based test demonstrated efficacy and high specificity in detecting multiple cancer types with diverse biological features, paving the way for a new screening option, according to research published in Annals of Oncology.

Treatment with hepatic arterial infusion chemotherapy in combination with sintilimab allowed for surgical resection and produced survival rates similar to lesser advanced hepatocellular carcinoma, according to a presenter at The International Liver Congress.

Intensive surveillance following esophageal cancer surgery improved oncologic outcomes, according to data presented at ASCO 2021.

Gastric cancer populations that show higher rates of phosphorylated signal transducer and activator of transcription 3 were more likely to have a shorter medial overall survival rate , according to data from a three phase 3 clinical trials presented at ASCO.

For patients with 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma, adding bemarituzumab to modified FOLFOX6 treatment improved overall survival vs. mFOLFOX 6 alone, according to data from a phase 2 study presented at ASCO21.

FDA’s Oncologic Drugs Advisory Committee today voted 13 to 4 to recommend deferral of a regulatory decision on retifanlimab for the treatment of certain patients with squamous cell carcinoma of the anal canal.

A high percentage of patients undergoing treatment for cancer achieved a sufficient antibody response to the BNT162b2 messenger RNA COVID-19 vaccine, according to study results published in JAMA Oncology.

Though clinical guidelines specify that oncologists should talk with patients about the risks for treatment-induced infertility, many patients with colon and rectal cancer report they did not receive or do not remember receiving information from their health care providers, according to a presentation at ASCO21 Annual Meeting.